DeepMed Research

BAYLOR COLLEGE OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1900-10-30

Employees: 10K

Market Cap: -

Website: http://www.bcm.edu

Clinical Trials

DiaBetter Together for Young Adults with Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Behavioral: Peer Mentor Delivery
Behavioral: DiaBetter Together

First Posted Date: 2020-01-30

Last Posted Date: 2024-10-10

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 144

Registration Number: NCT04247620

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Chimeric Antigen Receptor T-cells for the Treatment of AML Expressing CLL-1 Antigen

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Biological: CLL-1.CAR T cells

First Posted Date: 2020-01-06

Last Posted Date: 2024-10-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 18

Registration Number: NCT04219163

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU

Suspended

Conditions: Premature Infants

First Posted Date: 2019-12-09

Last Posted Date: 2025-02-24

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 120

Registration Number: NCT04190875

Locations: 🇺🇸
Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States

Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder

Phase 4

Completed

Conditions: Insomnia
Post-traumatic Stress Disorder

Interventions: Drug: Pimavanserin

First Posted Date: 2019-12-05

Last Posted Date: 2022-08-31

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 6

Registration Number: NCT04188392

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States

Prospective Study FNB, Is It Time To Abandon Cytological Assessment

Completed

Conditions: Pancreatic Neoplasms

First Posted Date: 2019-11-15

Last Posted Date: 2023-10-12

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 52

Registration Number: NCT04165018

Locations: 🇺🇸
Baylor St. Lukes Medical Center (BSLMC), Houston, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Phase 1

Recruiting

Conditions: Pancreatic Adenocarcinoma
Pancreatic Cancer
Pancreatic Adenosquamous Carcinoma

Interventions: Biological: Autologous DC Therapy

First Posted Date: 2019-11-08

Last Posted Date: 2025-05-23

Lead Sponsor: Diakonos Oncology Corporation

Target Recruit Count: 18

Registration Number: NCT04157127

Locations: 🇺🇸
Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
🇺🇸
Baylor St. Lukes Medical Center, Houston, Texas, United States
🇺🇸
Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States

Causal Mechanisms in Adolescent Arterial Stiffness

Phase 2

Recruiting

Conditions: Insulin Resistance Syndrome
Aortic Stiffness
Pediatric Obesity
Lipid Disorder
Metabolic Syndrome
Dyslipidemias

Interventions: Dietary Supplement: CS+
Dietary Supplement: CS-

First Posted Date: 2019-10-16

Last Posted Date: 2024-05-03

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 90

Registration Number: NCT04128969

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD

Not Applicable

Completed

Conditions: Autism Spectrum Disorder
Obsessive-Compulsive Disorder
Specific Phobia
Cognitive Behavioral Therapy
Anxiety Disorders
Generalized Anxiety Disorder
Social Anxiety Disorder

Interventions: Behavioral: Cognitive Behavioral Teletherapy LTA
Behavioral: Cognitive Behavioral Teletherapy STA

First Posted Date: 2019-10-01

Last Posted Date: 2025-01-15

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 87

Registration Number: NCT04111874

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

C7R-GD2.CAR T Cells for Patients with GD2-expressing Brain Tumors (GAIL-B)

Phase 1

Recruiting

Conditions: Diffuse Intrinsic Pontine Glioma
High Grade Glioma
Embryonal Tumor
Ependymal Tumor

Interventions: Genetic: C7R-GD2.CART cells (ICV infusion)
Genetic: C7R-GD2.CART cells (IV infusion)

First Posted Date: 2019-09-23

Last Posted Date: 2025-03-13

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 37

Registration Number: NCT04099797

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Phase 1

Withdrawn

Conditions: Hepatocellular Carcinoma
Hepatoblastoma

Interventions: Genetic: TEGAR T cells
Drug: Cytoxan
Drug: Fludarabine

First Posted Date: 2019-09-18

Last Posted Date: 2020-05-20

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT04093648

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy